Friday, April 27, 2018

Understanding Validation and Technical Transfer, Part 2

A validation plan developed to support a process unrelated to bio- pharmaceutical manufacture is applied to bio- pharmaceutical processes and systems.

Wright Studio/Shutterstock.com

This second installment in a three-part series on validation and technical transfer in the biopharmaceutical industry presents a generalized example that shows how a validation plan might be developed to support a process. While the example is not related to biopharmaceutical manufacture, it demonstrates various points to consider related to the inputs, the processing system, and the outputs that can be applied to biopharmaceutical processes and systems. The intent is to think outside the box and avoid terminology traps that hinder many validation efforts. 

Part 1 of this series, which appeared in the April 2018 issue of this publication, contained a brief history of validation and defined the terms process and validation to provide context (1).
 

An Example

Let’s say one is about to open a coffee shop and wants to ensure its success. The process to be validated is coffee-brewing. The goal is to consistently produce good tasting coffee. For the sake of simplicity, no specialty coffee (e.g., latte, cappuccino) is considered and no cream, sugar, or flavoring is added to the brewed coffee. The process is described as the following:

  • Inputs include water and coffee.
  • The processing system is the coffee brewer and the coffee grinder.
  • The outputs are brewed coffee and process waste: coffee grounds and used filters.

The process seems simple enough, but to begin with the end in mind, it is important to define good-tasting coffee. A controlled, double-blind study should be conducted to determine which coffee the majority of 
tasters prefer to obtain a definition of “good-tasting coffee.” To have a meaningful result, the brewed coffee used in the study must be produced in some standardized way not only to achieve reproducible tasting results but to enable the ultimately chosen brewing process to be validated and to produce coffee equivalent to that used in the tasting study. The obvious analogy is a clinical trial followed by subsequent commercial-scale production of a biopharmaceutical product.

The process inputs are water and coffee; but what type of coffee is selected and how is it roasted and ground? Should the coffee be a blend, or should it be a single type? If a blend is desired, what types should be used and in what proportion? Should the coffee be sourced from various growing regions or should it be single-sourced? What level of roast should be used: light, medium, dark? How will the roasting be controlled? How will the beans be ground, and to what degree? Should there be a maximum time allowed between grinding and brewing? Will tap water be used, or should some form of processed or filtered water be considered? These decisions impact the process and must be carefully considered. Some process variables are more critical than others.

Even in this simple example, there are many factors to consider, and biopharmaceutical processing is much more complex. An Ishikawa (fishbone) diagram is a helpful tool for visualizing processes and process inputs. 
Figure 1 is an example applied to coffee brewing.

Figure 1. Fishbone diagram of a simplified coffee-brewing process.

Once the decisions have been made with respect to the coffee and water, supported by evidence from the tasting trials, the brewing process can be considered. Data from how the coffee used in the tasting studies was prepared serve as the basis for developing and validating the brewing process. Wherever possible, quantitative values should be established and documented so they can be used for process execution and further evaluation. Equipment make, type, model, and serial number should be documented.

The brewing process must be carefully assessed before validation can begin. What brewing process will be used—percolation, drip, vacuum, or French press? Assuming the coffee type and grind have been determined, what brewing ratio, coffee-to-water, will be used? How long will the brewing cycle be? How will it be timed? What water temperature will be used, and when and how will that temperature be measured and controlled? What, if any, type of filter is employed? How will the brewing equipment be cleaned and when? Will detergents be used? If so, what duration and type of rinsing will be used to remove detergent residues?

The coffee brewed for the tasting studies will have been prepared in some controlled manner using identifiable coffee type, roast, and grind, and processed in equipment that will serve as the basis for selecting equipment for the commercial brewing process. Once the choice of equipment has been finalized, the equipment must be qualified with respect to its operational parameters. What brew settings are available? Which ones have a critical impact on the taste of the brewed coffee? How reproducible are the settings, and how accurate? With respect to the coffee grinder, how is the fineness of the grind determined and set? How reproducible are the settings? What is the uniformity of the grind? Does it contain a high proportion of “fines” or large particles? What are the capacities of the brewer and grinder and do they match the expected coffee shop volume?
Finally, the process output must be examined and evaluated. Does the brewed coffee taste good? How will that be determined? Is it the same as the coffee chosen as a result of the taste testing? Are there any analytical methods that might provide confirmation? At what temperature should the coffee be held, and for how long? How should it be served, in a paper cup, foam cup, or china? Does the cup require insulation? Will take-out be available? If reusable, how will the cups be washed? Are coffee stains or detergent residue issues?
Once these variables have been defined, examined, and evaluated, the validation study can begin. A single validation protocol can cover the entire process or, more usefully, the process can be broken down into several manageable steps with individual protocols for each.

Validation Protocols

Validation protocols should describe the intended process, define the acceptance criteria, and set forth the procedures and tests that will be used to demonstrate that the process does what it is intended to do and results in an output that meets the predetermined acceptance criteria. Ideally, the protocol should be written by those most familiar with the process to be validated, with input from other organizational units as necessary and appropriate. Development, process engineering, production, and regulatory affairs departments should almost always be involved. Other departments that might have input are purchasing, warehousing, and compliance. The quality assurance department must be involved at all phases of protocol development and must approve the final protocol before validation begins.

Protocols fit two broad categories. Qualification protocols are used for process equipment, such as tanks, mills, piping systems, autoclaves, ion exchange units, chromatography columns, and stopper washers. Validation protocols are used for processes that employ the qualified equipment and for processes related to the equipment, such as cleaning and sterilization.

It is convenient to break down equipment qualification into several steps such as design, installation, and operational as described below for the coffee brewing example.

Tasting studies may have shown that customers preferred coffee produced by pouring hot water through ground coffee supported on a filter. The proportions of coffee and water as well as the coffee type and grind, filter type, the brewing time, and the temperature were known from the development studies used to support the tasting. Adequate design qualification used in equipment selection will ensure the commercial brewer and grinder will meet the process requirements established during development. Factors to be considered include materials of construction, ease of use, space requirements, utilities, and process interactions (e.g., compatibility, adsorption, and leachables), and cleaning and maintenance.

Once selected, the equipment is installed, ensuring that electrical and water supplies are available and adequate and that necessary operational and storage space for supplies is convenient and available. The shop must be set up and arranged to optimize workflow. Space and facilities for equipment cleaning must also be available. Processing settings and conditions must be checked and calibration of water temperature, flow rate controls, and timers must be accomplished and documented. Cleaning procedures must be performed and evaluated for effectiveness and any problems corrected.

The installed and qualified equipment may then be used in start-up and training exercises to ensure everything, including coffee shop staff, is ready for a successful opening day.

Validation of the coffee brewing process may take place during the operational phase of equipment qualification, although the validation studies extend backward and forward in time. Earlier activities include vendor qualification of the coffee supplier and roaster, qualification and validation of the water supply system, validation of the equipment cleaning processes, and any calibration programs and maintenance procedures. Later activities include periodic evaluations to ensure the brewing process is functioning as intended, evaluation of cleaning and maintenance procedures to ensure adequate frequency and effectiveness, and a review to determine whether any operational issues or employee training programs need to be adjusted.
This good-tasting coffee example is intended to stimulate thinking about the important points to consider when developing and marketing a product that consistently meets customer expectations. Although the product in question, good-tasting coffee, is not a biopharmaceutical, the same validation principles apply. The validated process must be robust, consistent, and do what it is intended to do.

Part 3 of this series will discuss validation of a non-traditional biopharmaceutical process, lifecycle, and change management and offers a summarization of the benefits of well-conceived and executed process validation studies.

Reference

1. R. Madsen, BioPharm International 31 (4) 26-30 (April 2018).

Article Details

BioPharm International
Vol. 31, No. 5
May 2018
Pages: 36-39

Citation

When referring to this article, please cite it as R. Madsen, “Understanding Validation and Technical Transfer, Part 2” BioPharm International  31 (5) 2018.

 

Source link

Applied Statistics for FDA Process Validation (Philadelphia, PA, United States – May 17th-18th, 2018) – ResearchAndMarkets.com | Business

DUBLIN–(BUSINESS WIRE)–Apr 26, 2018–The “Applied Statistics for FDA Process Validation” conference has been added to ResearchAndMarkets.com’s offering.

Course “Applied Statistics for FDA Process Validation” has been pre-approved by RAPS as eligible for up to 12 credits towards a participant’s RAC recertification upon full completion.

Stage 1: Process Design: The commercial manufacturing process is defined during this stage based on knowledge gained through development and scale-up activities.

Stage 2: Process Qualification: During this stage, the process design is evaluated to determine if the process is capable of reproducible commercial manufacturing.

Stage 3: Continued Process Verification: Ongoing assurance is gained during routine production that the process remains in a state of control.

Who Will Benefit:

This seminar is designed for pharmaceutical and biopharmaceutical professionals who are involved with product and/or process design, validation, or manufacturing/control.Process Scientist/EngineerDesign EngineerProduct Development EngineerRegulatory/Compliance ProfessionalDesign Controls EngineerSix Sigma Green BeltSix Sigma Black BeltContinuous Improvement Manager

For more information about this conference visit https://ift.tt/2r2Q90S

View source version on businesswire.com:https://ift.tt/2HzEtsL

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Pharmaceutical Manufacturing

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 04/26/2018 06:21 PM/DISC: 04/26/2018 06:21 PM

https://ift.tt/2r0Dv2s

Copyright Business Wire 2018.

Source link

Cambrex hiring 12 new analytical scientists post $3.2m expansion

LSNE Announces Acquisition Of PSC Biotech’s Parenteral Manufacturing Facility – News Press Release

LSNE Announces Acquisition Of PSC Biotech’s Parenteral Manufacturing Facility

Lyophilization Services of New England
Posted on: 26 Apr 18

BEDFORD, N.H., April 24, 2018 /PRNewswire/ — Lyophilization Services of New England (LSNE), a leading contract development and manufacturing organization (CDMO), today announced that it has acquired PSC Biotech’s cGMP aseptic fill finish manufacturing facility located in Madison, Wisconsin.   This acquisition allows LSNE to expand its manufacturing capabilities, add new service offerings and accommodate its customers’ project timing requirements.   The new facility will be called LSNE-Madison.  Financial terms of the transaction were not disclosed.

LSNE-Madison is a 37,000 square foot multi-product facility that will be used for the manufacturing of final drug products for pre-clinical to Phase III/commercial use.  The facility currently includes a high speed, automated aseptic fill line and a 144-square foot lyophilizer with existing space for additional equipment and the ability to expand to over 100,000 square feet of production space over time. 

The facility will complement LSNE’s existing full-service parenteral manufacturing capabilities, which include vial filling, lyophilization, process development, QC analytical, secondary packaging, stability studies and regulatory support for clinical and commercial products at its three other FDA-inspected manufacturing sites.  This new facility will also increase LSNE’s capabilities to include the terminal sterilization of final product and additional quality control services. 

“This acquisition is a key part of our strategic growth plan to increase our operations and capacity and better serve our customers,” said Matthew Halvorsen, Chief Executive Officer at LSNE.  “We have experienced strong growth and increased demand over the last few years, and as the market continues to expand, we know it is imperative to be able to offer increased scheduling flexibility to existing and new clients. With the support of the Permira Funds, we are increasing our capacity to provide our clients with additional manufacturing redundancy backed by the outstanding level of service that LSNE is known for.”   

“With this acquisition, we are gaining strong talent that complements LSNE’s experienced and successful teams,” says Shawn Cain, Chief Operation Officer at LSNE.  “We look forward to working with the staff to build LSNE-Madison into a world class aseptic fill/finish facility focused on the manufacturing of lyophilized and liquid drug products. “

LSNE anticipates full manufacturing activities to commence later this year, following a short period of renovation and validation of the facility.  Additional information regarding the acquisition and capabilities will be available on LSNE’s website.

About LSNE

LSNE is a privately held company with four GMP facilities – three located in New England and one in Madison, WI.  LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology and medical device industries since 1997, specializing in a wide range of services including cycle development, cGMP fill finish, and lyophilization.  Through the thoughtful integration of four processing facilities, qualified staffing, and an extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a multi-national market.

About PSC Biotech

PSC Biotech is global life sciences technology company serving customers in North America, Europe, Asia, South America and the Middle East.  PSC Biotech provides professional technical services such as commissioning, qualification, validation project management, regulatory affairs, quality, compliance, conceptual engineering, Information Technology, metrology services, computerized system validation, etc., to life science, pharmaceutical and software companies.  It also provides world class enterprise quality management software solutions – Adaptive Compliance Engine™ (ACE) and AuditUtopia™.

Media Contact

Christine Palus

Vice President of Sales & Marketing

(603) 668-5763

info@lyophilization.com

www.lyophilization.com

Editor’s Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 26/04/2018

Source link

Thursday, April 26, 2018

Pharmaceutical Glass Ampoules Market Manufacturers, Data Validation, Scope, Drivers and Forecast 2023 – Healthcare News

Pharmaceutical Glass Ampoules Market Report 2018 provide emerging opportunities in the Industry and its growth prospects over the coming years. Report includes the Pharmaceutical Glass Ampoules industry company profile, Main Business Information, SWOT Analysis, Sales, Revenue, Price and Gross Margin, and market shares for each company as well as Pharmaceutical Glass Ampoules Market report also contains Consumption, Sales, production value, cost/profit, supply/demand, import/export, Analysis of Industry Chain Structure, Economic Impact, Market Dynamics, and Proposals for New Project is also added.

Pharmaceutical Glass Ampoules Market report covers data on regional markets including CAGR of XX% from 2018 to 2023., historical and future trends for supply, market size, prices, trading, competition and value chain as well as major vendor’s information.

Ask PDF Sample for More Details of Pharmaceutical Glass Ampoules Market Report at https://ift.tt/2HQOwNn

Pharmaceutical Glass Ampoules Market Competitor Segment: The report includes global key players as well as some small players. The Information of Pharmaceutical Glass Ampoules Market for Each Competitor Includes:

  • Company Profile
  • Main Business Information
  • SWOT Analysis
  • Sales, Revenue, Price and Gross Margin
  • Market Share

View More Details of Pharmaceutical Glass Ampoules Market Report at https://ift.tt/2vP41QT

Pharmaceutical Glass Ampoules Market Geography Segment, Regional Supply, Application-Wise and Type-Wise Demand, Major Players, Price Is Presented from 2013 To 2023. This Report Covers Following Regions:

  • North America
  • South America
  • Asia & Pacific
  • Europe
  • MEA (the Middle East and Africa)

The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

There Are 11 Chapters to Deeply Display the Pharmaceutical Glass Ampoules Market, 2023 Research Report.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and major Pharmaceutical Glass Ampoules Market players in detail.

Price of Report: $ 4000 (Single User Licence)

Purchase at https://ift.tt/2HUSLr4

In this part, the report presents the Research Scope, Methodology, Data Collection, Data Analysis and Research Sources of Pharmaceutical Glass Ampoules Market.

Through the statistical analysis, the report depicts the global total market of Pharmaceutical Glass Ampoules Market including Market Landscape, Trend Analysis (Drivers, Restraints, Opportunities, and Threats), Industry Chain Analysis, Latest Market Dynamics and Trading Analysis of Pharmaceutical Glass Ampoules Market.

Through the Historical and Current Pharmaceutical Glass Ampoules Market in the region, the report depicts the global total market of Pharmaceutical Glass Ampoules Market including Supply, Demand by End Use, Competition by Players/Suppliers, Type Segmentation and Price and Key Countries Analysis

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2018-2023 market development trends of Pharmaceutical Glass Ampoules Market.

 

Source link